Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 5447

1.

Claims for disease-modifying therapy by Alberta non-insured health benefits clients.

Barnabe C, Healy B, Portolesi A, Kaplan GG, Hemmelgarn B, Weaselhead C.

BMC Health Serv Res. 2016 Aug 24;16(1):430. doi: 10.1186/s12913-016-1685-y.

2.

Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.

Levy RA, de Jesús GR, de Jesús NR, Klumb EM.

Autoimmun Rev. 2016 Aug 1. pii: S1568-9972(16)30159-8. doi: 10.1016/j.autrev.2016.07.014. [Epub ahead of print] Review.

PMID:
27490204
3.

The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).

Weiner M, Segelmark M.

Autoimmun Rev. 2016 Jul 29. pii: S1568-9972(16)30161-6. doi: 10.1016/j.autrev.2016.07.016. [Epub ahead of print] Review.

PMID:
27481040
4.

Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children.

Davies HD; COMMITTEE ON INFECTIOUS DISEASES.

Pediatrics. 2016 Aug;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209. Epub 2016 Jul 18.

PMID:
27432853
5.

The role of adipose stem cells in inflammatory bowel disease: from biology to novel therapeutic strategies.

De Francesco F, Romano M, Zarantonello L, Ruffolo C, Neri D, Bassi N, Giordano A, Zanus G, Ferraro GA, Cillo U.

Cancer Biol Ther. 2016 Jul 14:0. [Epub ahead of print]

PMID:
27414952
6.

Bilateral lower limb weakness in acute severe ulcerative colitis.

Lynch RW, Soane T, Gibson R, Pal S, Lees CW.

Lancet. 2016 Jul 2;388(10039):101-2. doi: 10.1016/S0140-6736(16)30857-1. No abstract available.

PMID:
27397791
7.

Health Care Maintenance in Adolescents with Inflammatory Bowel Disease.

Rufo PA, Egberg MD.

Adolesc Med State Art Rev. 2016 Spring;27(1):177-92. Review. No abstract available.

PMID:
27363240
8.

Advances in Pediatric Inflammatory Bowel Disease.

Maxwell EC, Grossman AB.

Adolesc Med State Art Rev. 2016 Spring;27(1):57-74. Review. No abstract available.

PMID:
27363233
9.

PREGNANCY, CROHN'S DISEASE AND AZATHIOPRINE: A CASE STUDY AND LITERATURE REVIEW.

Austin J, Vaccaro A.

Aust Nurs Midwifery J. 2016 Apr;23(9):28-31. Review. No abstract available.

PMID:
27254988
10.

[Ulcerative colitis].

Roose L, D'cunja J, Biedermann L.

Praxis (Bern 1994). 2016 May 25;105(11):607-15. doi: 10.1024/1661-8157/a002358. Review. German.

PMID:
27223413
11.

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 18;(5):CD000478. doi: 10.1002/14651858.CD000478.pub4. Review.

PMID:
27192092
12.

Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video).

Rajan E, Gostout CJ, Wong Kee Song LM, Szarka LA, Kashyap PC, Smyrk TC, Bingener J, Deters JL, Knipschield MA, Bernard CE, Farrugia G.

Gastrointest Endosc. 2016 Sep;84(3):512-7. doi: 10.1016/j.gie.2016.04.029. Epub 2016 Apr 27.

PMID:
27129395
13.

Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy.

Zatorski H, Marynowski M, Fichna J.

Pharmacol Rep. 2016 Aug;68(4):809-15. doi: 10.1016/j.pharep.2016.03.006. Epub 2016 Mar 18. Review.

PMID:
27117379
14.

[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].

Rutka M, Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Molnár T.

Orv Hetil. 2016 May 1;157(18):706-11. doi: 10.1556/650.2016.30429. Hungarian.

PMID:
27106726
15.

Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.

Gisbert JP, Chaparro M.

Aliment Pharmacol Ther. 2016 May;43(9):1020. doi: 10.1111/apt.13579. No abstract available.

PMID:
27040169
16.

Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.

Macaluso FS, Criscuoli V, Orlando E, Rizzuto G, Renna S, Cottone M, Orlando A.

Aliment Pharmacol Ther. 2016 May;43(9):1019-20. doi: 10.1111/apt.13565. No abstract available.

PMID:
27040168
17.

Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply.

Yamamoto T, Shimoyama T, Umegae S, Matsumoto K.

Aliment Pharmacol Ther. 2016 May;43(9):1017-8. doi: 10.1111/apt.13578. No abstract available.

PMID:
27040167
18.

Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis.

Taylor KM, Sparrow MP.

Aliment Pharmacol Ther. 2016 May;43(9):1016-7. doi: 10.1111/apt.13575. No abstract available.

PMID:
27040166
19.

Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN.

Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1.

PMID:
27039969
20.

Distribution of Cytomegalovirus DNA Load in the Inflamed Colon of Ulcerative Colitis Patients.

Pillet S, Williet N, Pouvaret A, Del Tedesco E, Saint-Sardos P, Pozzetto B, Roblin X.

Am J Gastroenterol. 2016 Mar;111(3):439-41. doi: 10.1038/ajg.2016.27. No abstract available.

PMID:
27018121
Items per page

Supplemental Content

Loading ...
Write to the Help Desk